Cresilon to Present Groundbreaking TRAUMAGEL Study at Military Health System Research Symposium 2025
Cresilon Inc., a pioneering biotechnology firm based in Brooklyn, has announced a significant milestone in its journey to advance hemostatic medical technology. The company will present a detailed case study on its FDA-cleared hemostatic device, TRAUMAGEL®, at the highly anticipated Military Health System Research Symposium (MHSRS) 2025. This annual event, scheduled from August 4-7 in Kissimmee, Florida, serves as the premier gathering for the exchange of scientific knowledge aimed at addressing the unique medical needs of military personnel.
The presentation, titled 'A Case Study Demonstrating the Utility of TRAUMAGEL® in Emergency Hemorrhagic Trauma Setting,' is set to be delivered by Dr. Dhanushka Vitharana, M.D., from the Louisiana State University Health Science Center. This session focusing on hemorrhage control and vascular dysfunction will take place on August 5 from 3:30 PM to 5:30 PM EDT at the Gaylord Palms Resort and Convention Center.
TRAUMAGEL® has been strategically designed for rapid deployment in emergency situations, effectively controlling bleeding in just seconds. Cresilon representatives will be on hand at the poster session and at Booth #1013, where they will elaborate on the practical applications of this innovative device within emergency response and military settings. Attendees will have the opportunity to see how TRAUMAGEL® stands out as a state-of-the-art solution for trauma care, potentially revolutionizing the way hemorrhagic injuries are treated in the field.
The MHSRS serves as a vital platform for military and civilian health professionals, researchers, and industry leaders. It promotes collaboration and information exchange on research initiatives and healthcare strategies vital to the warfighter. Cresilon's participation underscores its commitment to addressing not just civilian medical needs but also those of courageous military personnel who often find themselves in critical scenarios requiring swift medical intervention.
Cresilon's dedication to innovation does not go unnoticed; the company was recognized in Fast Company’s annual list of the World’s Most Innovative Companies in 2024, ranking first in the medical devices category. By harnessing its proprietary hydrogel technology, Cresilon has developed products that aim to stop bleeding in record time, thus enhancing survival rates and patient outcomes in trauma situations.
The company is focused not only on trauma care but also has plans to expand into biosurgery and animal health markets in the future. This broader vision aligns with Cresilon's mission to save lives through innovative technological advancements.
For those who cannot attend the symposium, Cresilon plans to make the poster presentation available online shortly after the conference concludes. More information, including access to the poster and details about TRAUMAGEL®, can be found on Cresilon’s website at https://cresilon.com/traumagel.
As the healthcare landscape continues to evolve, innovations like TRAUMAGEL® highlight the importance of medical advancements tailored to meet the needs of both military and civilian populations. Cresilon’s initiative at MHSRS 2025 is just one example of how biotechnological innovations can lead to significantly improved patient care and outcomes in urgent situations.
The presentation, titled 'A Case Study Demonstrating the Utility of TRAUMAGEL® in Emergency Hemorrhagic Trauma Setting,' is set to be delivered by Dr. Dhanushka Vitharana, M.D., from the Louisiana State University Health Science Center. This session focusing on hemorrhage control and vascular dysfunction will take place on August 5 from 3:30 PM to 5:30 PM EDT at the Gaylord Palms Resort and Convention Center.
TRAUMAGEL® has been strategically designed for rapid deployment in emergency situations, effectively controlling bleeding in just seconds. Cresilon representatives will be on hand at the poster session and at Booth #1013, where they will elaborate on the practical applications of this innovative device within emergency response and military settings. Attendees will have the opportunity to see how TRAUMAGEL® stands out as a state-of-the-art solution for trauma care, potentially revolutionizing the way hemorrhagic injuries are treated in the field.
The MHSRS serves as a vital platform for military and civilian health professionals, researchers, and industry leaders. It promotes collaboration and information exchange on research initiatives and healthcare strategies vital to the warfighter. Cresilon's participation underscores its commitment to addressing not just civilian medical needs but also those of courageous military personnel who often find themselves in critical scenarios requiring swift medical intervention.
Cresilon's dedication to innovation does not go unnoticed; the company was recognized in Fast Company’s annual list of the World’s Most Innovative Companies in 2024, ranking first in the medical devices category. By harnessing its proprietary hydrogel technology, Cresilon has developed products that aim to stop bleeding in record time, thus enhancing survival rates and patient outcomes in trauma situations.
The company is focused not only on trauma care but also has plans to expand into biosurgery and animal health markets in the future. This broader vision aligns with Cresilon's mission to save lives through innovative technological advancements.
For those who cannot attend the symposium, Cresilon plans to make the poster presentation available online shortly after the conference concludes. More information, including access to the poster and details about TRAUMAGEL®, can be found on Cresilon’s website at https://cresilon.com/traumagel.
As the healthcare landscape continues to evolve, innovations like TRAUMAGEL® highlight the importance of medical advancements tailored to meet the needs of both military and civilian populations. Cresilon’s initiative at MHSRS 2025 is just one example of how biotechnological innovations can lead to significantly improved patient care and outcomes in urgent situations.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.